RxDoctor Payments Data

Nisha Desai, MD

Dermatology · Portland, ORNPI 1265605984

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Eli Lilly at 53.3% of the total. Reporting peaked in 2022 at $5,678 and has fallen 96.6% since, to $192 in 2025.

$9,986in general payments, 2019–2025

Across 128 payments — averaging $78.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$5K
  • Pfizer$3K
  • AbbVie$631
  • Johnson & Johnson$271
  • Novartis$245
  • Janssen Scientific Affairs, LLC$148
  • plus $504 from 12 others
$1,284,035in research payments, 2019–2025

Across 91 payments — averaging $14,110 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$641K
  • Sun Pharmaceutical Industries Inc.$383K
  • Pfizer$162K
  • Arcutis Biotherapeutics, Inc.$70K
  • Eli Lilly$19K
  • Amgen$10K

What the payments were for

  • Consulting fees$4,90049%
  • Travel & lodging$2,73027%
  • Food & beverage$2,15922%
  • Education$1972%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,986 in reported general payments places this provider in the 85th percentile of 175 dermatology providers in Oregon.

See all dermatology providers in Oregon

Medicare billing

Part B allowed, 2024
$114,628
Medicare patients
434
Services billed
1,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Minoxidil470$6,504
Hydroxychloroquine Sulfate84$3,657
Hydrocortisone Butyrate17$2,506
Doxycycline Monohydrate74$2,494
Betamethasone Valerate58$2,265
Doxycycline Hyclate42$2,032
Betamethasone Dipropionate63$1,960
Clobetasol Propionate59$1,801
Tacrolimus20$1,518
Ketoconazole65$1,104
Finasteride134$1,023
Mometasone Furoate37$820
Triamcinolone Acetonide50$663
Minocycline Hcl20$572
Spironolactone24$515

Paid to pharmacies, not to this prescriber.

Other dermatology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →